GENE vs CRA EARNINGS COMPARISON for latest reported quarters.
CRA lost .94 cents last quarter and is trading currently at $232 GENE only lost .01 and is currently trading at 22 7/8. The balance sheets for the two companies are no contest with GENE looking far better and it should be just a matter of time that more Brokerages and Fund Managers see this and initiate coverage as that seems to be the deciding factor for CRA trading over 10 times the price of GENE right now.
Jan. 6 /PRNewswire/ -- Genome Therapeutics Corp.
(Nasdaq: GENE) today reported financial results for the first quarter of
fiscal 2000, which ended November 27, 1999. Total revenues for the first
quarter of fiscal 2000 were $6,035,000, compared to $5,110,000 in the same
period of fiscal 1999. Net loss in the first quarter of fiscal 2000 was
($122,000), or ($0.01) per share, compared to a net loss of ($2,472,000), or
($0.13) per share, for the same period in fiscal 1999.
(NYSE:CRA), a PE Corporation business, today reported revenues
of $8.3 million for the second quarter of fiscal year 2000, ended December 31, 1999, compared to $1.7 million for the second quarter of fiscal 1999. The operating loss for the second quarter of fiscal 2000 was $39.3 million, versus $12.9 million for the prior year's second quarter.
The net loss for the second quarter of fiscal 2000, after
credit for taxes, was $24.3 million, or $0.94 per share , compared to a net loss of $8.6 million, or $0.35 per share, for the same period last year
T A P has taken a position in GENE on the open market and is not compensated in any way by any company mentioned! All information can not be guaranteed but is believed accurate and is for purpose of research and is not a solicitation to buy any security and doing so will be done at your own risk. For more information on GENE see other posts on this and T A P General Topic & Internet/Biotech message boards. To join T A P free go to T A P profile for url. |
